[Health effects of diesel exhaust: a state of the art]. / Effets sur la santé des émissions des moteurs diesel: revue des connaissances.

INTRODUCTION: This review presents the state of knowledge regarding the acute and chronic toxicity of diesel engine exhaust in humans. STATE OF ART: The health effects of diesel engine exhaust, which is a complex mixture of gas and particulate matter (ultrafine and fine particles), are mainly irritation of the respiratory tract and carcinogenicity. They may also facilitate the development of respiratory allergies. A recent reassessment by the International Agency for Research on Cancer concluded that there is sufficient evidence of a causal association between exposure to diesel engine exhaust and lung cancer. PERSPECTIVES: The epidemiologic data collected during the last two decades also show limited evidence of increased risks of bladder cancer, as well as of chronic obstructive pulmonary disease in diesel engine exhaust exposed workers. Both experimental and epidemiological studies have involved the effect of emissions from traditional diesel engine technology. Major developments in this technology have occurred recently and the toxicity of emissions from these new engines is still to be characterized. CONCLUSION: Further studies are needed to explore the link between diesel engine exhaust exposure and the risks of bladder cancer, as well as of chronic obstructive pulmonary disease and respiratory allergies. Research is also needed to get more information about the toxicity of the new diesel technology emissions.

[Thrombosis of atrioventricular prosthesis. Contribution of transesophageal echocardiography]. / Thromboses de prothèses en position auriculo-ventriculaire. Apport de l'échocardiographie transoesophagienne.

The aim of this study was to assess the diagnostic value of transesophageal echocardiography for the detection of thrombosis of a mechanical mitral or tricuspid valve prosthesis. Twelve patients (mean age 54 +/- 12 years) out of a series of 39 patients operated between April 1988 and June 1989 for prosthetic valve dysfunction had valve thrombosis at operation (11 mitral and 1 tricuspid valve prosthesis). Transesophageal echocardiography was routinely performed preoperatively in addition to transthoracic Doppler echocardiography to search for an abdominal mass on the prosthetic valves. The largest diameter of the diastolic jet at the level of the prosthetic valve annulus was measured using transesophageal color flow Doppler in the 8 Starr-Edwards mitral valve prostheses and compared with 5 control valves. The results of transthoracic Doppler echocardiography and transesophageal echocardiography were compared with the operative findings. The specificity of transthoracic echocardiography for the positive diagnosis of prosthetic valve thrombosis was 18%. A thrombosis could be suspected in 10 of the 12 cases by transthoracic echocardiography giving a sensitivity of 83%. Eleven of the 12 abnormal masses on the prostheses were visualised by transesophageal echocardiography, a sensitivity of 91%. Detection of the masses on the arterial side was possible in all cases (10/10) but 5 of the 6 extensions of the thrombus into the ventricle could not be visualised. The diameter of the transprosthetic jet was less than 12 mm in 7 of the 8 thrombosed valves compared with greater than 15 mm in the 5 normal control prostheses.(ABSTRACT TRUNCATED AT 250 WORDS)

[Study of valvular prostheses by Doppler echography]. / Etude des prothèses valvulaires en écho-Doppler.

Doppler echocardiography is a reliable non-invasive method of following up patients with prosthetic heart valves. Transthoracic M mode and two-dimensional echo allow evaluation of the movement of the mobile element of the prosthesis and of the size of the cardiac chambers. Doppler studies (transprosthetic pressure gradient, valve surface area, trans- and periprosthetic regurgitation) give an indication of the hemodynamic profile of the prosthesis. Transesophageal echocardiography is especially useful when there are abnormalities suggestive of prosthetic valve dysfunction (fever, systemic embolism, clinical symptoms, haemolysis...).

Effects of early high-dose streptokinase intravenously on left ventricular function in acute myocardial infarction.

One hundred seven patients who recently had acute myocardial infarction were randomly assigned either to standard heparin therapy or to intravenous streptokinase within 5 hours after the onset of symptoms in 7 hospitals without catheterization facilities. In the third week, the patients were referred to a university hospital, where the patency rate of the infarct-related artery was studied by selective coronary arteriography and left ventricular function by radionuclide angiography. Fifty-five patients received heparin and 52 streptokinase within a mean period of 190 minutes after the onset of symptoms. Seven patients in the heparin group and 4 in the streptokinase group died in hospital. The patency rate of the infarct-related artery was identical in both groups (69% in the heparin group vs 68% in the streptokinase group). Left ventricular ejection fraction was not statistically different (0.44 +/- 0.13 in the heparin group vs 0.45 +/- 0.12 in the streptokinase group). Left ventricular ejection fraction was significantly higher in patients with a patent infarct-related artery than in patients with an obstructed infarct-related artery (0.49 +/- 0.12 vs 0.41 +/- 0.15, p less than 0.01). In patients with inferior wall infarction, left ventricular ejection fraction was identical (0.50 +/- 0.10 in the heparin group vs 0.52 +/- 0.09, in the streptokinase group). In patients with anterior wall infarction, left ventricular ejection fraction was significantly higher in the streptokinase group than in heparin group (0.40 +/- 0.10 vs 0.33 +/- 0.09, p less than 0.05). Analysis of regional wall motion revealed that improvement occurred in the lateral wall of the left ventricle.(ABSTRACT TRUNCATED AT 250 WORDS)

[Intravenous streptokinase versus heparin in recent acute myocardial infarction. Randomized multicenter study in the Franche-Comté]. / Streptokinase intraveineuse versus héparine dans l'infarctus du myocarde aigu récent. Etude randomisée multicentrique franc-comtoise.

A multicentre randomised therapeutic trial was undertaken in 8 hospitals in the Franche-Comté department of France (Belfort, Besançon, Dole, Lons-le-Saunier, Luxeuil, Montbéliard, Vesoul, Pontarlier) in which 101 patients with acute primary myocardial infarction were treated within 5 hours of onset of symptoms with either intravenous streptokinase (1,500,000 U in 30 mn) or conventional heparin therapy. The results were assessed on the clinical outcome, arterial patency in the necrosed territory and global and regional ejection fractions (EF) at the 3rd week. After randomisation, 51 patients were given heparin and 50 received streptokinase. Seven patients died in the heparin group and 4 in the streptokinase group (NS). At the third week, the artery in the necrosed zone was patent in 69% of the heparin group and in 68% of the streptokinase group (NS). The EF was significantly higher in the patients with patent arteries in the necrosed zone than in those with occluded arteries (0.49 +/- 0.12 vs 0.41 +/- 0.15, p less than 0.01). There was no significant difference in EF between the heparin and streptokinase groups. The EF was significantly higher in patients with anterior infarction who received streptokinase than in those who received heparin (0.40 +/- 0.10 vs 0.33 +/- 0.09 p less than 0.05). Segmental wall motion was significantly better at the apex and free wall. There was no significant difference between the two groups in posterior infarction. These results show that reestablishment or maintenance of arterial patency in the necrosed zone improves left ventricular function and that patients with anterior wall infarction are the ones most likely to benefit from streptokinase therapy.